ES2145149T3 - Inhibicion de la migracion de celulas del musculo liso por (r)-amlodipina. - Google Patents

Inhibicion de la migracion de celulas del musculo liso por (r)-amlodipina.

Info

Publication number
ES2145149T3
ES2145149T3 ES94926189T ES94926189T ES2145149T3 ES 2145149 T3 ES2145149 T3 ES 2145149T3 ES 94926189 T ES94926189 T ES 94926189T ES 94926189 T ES94926189 T ES 94926189T ES 2145149 T3 ES2145149 T3 ES 2145149T3
Authority
ES
Spain
Prior art keywords
pct
amlodipine
smooth muscle
migration
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94926189T
Other languages
English (en)
Inventor
Suresh Babubhai Pfize Chahwala
Derek Paul Winslow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10741080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2145149(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2145149T3 publication Critical patent/ES2145149T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL ISOMERO R(+) DE AMLODIPINA ES UN POTENTE INHIBIDOR DE LA MIGRACION CELULAR DEL MUSCULO LISO A PESAR DE CARECER DE ACTIVIDAD DE BLOQUEO DEL CANAL DE CALCIO. ES UTIL PARA TRATAR LA ATEROESCLEROSIS, Y REESTENOSIS POSTERIOR A LA ANGIOPLASTIA Y A LA ENDOMETRIOSIS.
ES94926189T 1993-08-26 1994-08-10 Inhibicion de la migracion de celulas del musculo liso por (r)-amlodipina. Expired - Lifetime ES2145149T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939317773A GB9317773D0 (en) 1993-08-26 1993-08-26 Therapeutic compound

Publications (1)

Publication Number Publication Date
ES2145149T3 true ES2145149T3 (es) 2000-07-01

Family

ID=10741080

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94926189T Expired - Lifetime ES2145149T3 (es) 1993-08-26 1994-08-10 Inhibicion de la migracion de celulas del musculo liso por (r)-amlodipina.

Country Status (20)

Country Link
US (1) US6080761A (es)
EP (1) EP0754043B1 (es)
JP (2) JP3007992B2 (es)
KR (1) KR0163840B1 (es)
CN (1) CN1060039C (es)
AT (1) ATE192337T1 (es)
AU (1) AU686658B2 (es)
CA (1) CA2170278C (es)
DE (1) DE69424317T2 (es)
DK (1) DK0754043T3 (es)
ES (1) ES2145149T3 (es)
GB (1) GB9317773D0 (es)
GR (1) GR3033547T3 (es)
IL (1) IL110700A (es)
NO (1) NO308826B1 (es)
NZ (1) NZ271993A (es)
PT (1) PT754043E (es)
TW (1) TW470646B (es)
WO (1) WO1995005822A1 (es)
ZA (1) ZA946475B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
GB0020842D0 (en) 2000-08-23 2000-10-11 Pfizer Ltd Therapeutic compositions
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
CZ20031779A3 (cs) * 2000-12-29 2004-10-13 Bioorganicsáb@V Způsob přípravy amlodipinuŹ jeho derivátů a jejich prekurzorů
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
CN1152013C (zh) * 2001-11-22 2004-06-02 张喜田 一类左旋氨氯地平盐的水合物及其制剂
WO2006043148A1 (en) * 2004-10-20 2006-04-27 Emcure Pharmaceuticals Limited Process for producing enantiomer of amlodipine in high optical purity
KR100828883B1 (ko) * 2006-10-27 2008-05-09 씨제이제일제당 (주) 라세믹 암로디핀으로부터 ｓ-(-)-암로디핀의 분리방법
KR100830003B1 (ko) * 2006-10-31 2008-05-15 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8804630D0 (en) * 1988-02-27 1988-03-30 Pfizer Ltd Preparation of r-& s-amlodipine
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine

Also Published As

Publication number Publication date
CA2170278A1 (en) 1995-03-02
JP3007992B2 (ja) 2000-02-14
NZ271993A (en) 1997-11-24
CN1060039C (zh) 2001-01-03
CA2170278C (en) 1999-08-03
DK0754043T3 (da) 2000-08-07
DE69424317D1 (de) 2000-06-08
US6080761A (en) 2000-06-27
TW470646B (en) 2002-01-01
ZA946475B (en) 1996-02-26
AU7612994A (en) 1995-03-21
PT754043E (pt) 2000-09-29
GB9317773D0 (en) 1993-10-13
IL110700A (en) 1999-04-11
KR960703593A (ko) 1996-08-31
NO960730L (no) 1996-02-23
JP2000044475A (ja) 2000-02-15
EP0754043B1 (en) 2000-05-03
EP0754043A1 (en) 1997-01-22
CN1129907A (zh) 1996-08-28
KR0163840B1 (ko) 1998-12-01
AU686658B2 (en) 1998-02-12
JPH08509004A (ja) 1996-09-24
ATE192337T1 (de) 2000-05-15
DE69424317T2 (de) 2000-08-24
GR3033547T3 (en) 2000-09-29
NO308826B1 (no) 2000-11-06
NO960730D0 (no) 1996-02-23
WO1995005822A1 (en) 1995-03-02
IL110700A0 (en) 1994-11-11

Similar Documents

Publication Publication Date Title
ES2145149T3 (es) Inhibicion de la migracion de celulas del musculo liso por (r)-amlodipina.
NO983003L (no) Vitronectin-reseptor-antagonister
NO972043L (no) Tienopyridin eller tienopyrimidinderivater og deres anvendelse
DK0675714T3 (da) Kombination af en cholesterol-biosynteseinhibitor og en beta-lactam-cholesterolabsorptionsinhibitor
NO981810D0 (no) Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt
MY114701A (en) Process and crystal forms of 2-methyl-thieno- benzodiazepine
MY121222A (en) Prodrugs of thrombin inhibitors
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
BR8907430A (pt) Aparelho e metodo para aplicar polimeros pulverizados por chama de plasma
NO992821L (no) Ketobenzamider som calpain-inhibitorer
EP0651766A4 (en) INHIBITORS OF FACTOR Xa, DERIVED FROM THE INHIBITOR OF THE PANCREATIC TRYPSON FROM BEEF.
MY115310A (en) Substance p antagonists for the treatment of emesis
DK0896544T3 (da) Kombination af en somatostatinanalog og en rapamycin
IT1259419B (it) Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi
DK0773320T3 (da) Sikkerhedsark med i det væsentlige konstant tykkelse
DK0693169T3 (da) Fremgangsmåde til forbrænding af faststoffer på et skubbe-forbrændingsrist-system
IT1290173B1 (it) Procedimento per la produzione di lamierino di acciaio al silicio a grano orientato
ATE228760T1 (de) Thrombininhibitoren
DK0732926T3 (da) Farmaceutisk formulering til profylakse eller forbehandling af forgiftninger fremkaldt af organophosphor-cholinesterase-inhibitorer
NO982582L (no) Fremgangsmaate for behandling av smerte
ATE286560T1 (de) Vorrichtung zum brechen von beton oder dergleichen
PL326294A1 (en) Method of retarding the inhibitor 1 of plasminogene activator
ES2106098T3 (es) Lacidipino para el tratamiento de la arteriosclerosis.
BG105010A (en) Medicamentous form containing paroxetine
DK0434020T3 (da) 2,19-Methylenoxy- og 2,19-methylenthiobroforbundne steroider og deres anvendelse som inhibitorer af aromatase og 19-hydroxylase

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 754043

Country of ref document: ES